![Page 1: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/1.jpg)
Diagnostic imaging with Diagnostic imaging with 111In-DTPA-octreotide:111In-DTPA-octreotide:
Clinical impact on the management of Clinical impact on the management of patients with neuroendocrine tumourspatients with neuroendocrine tumours
Ulrike Garske MDUlrike Garske MD
Specialist in oncology, nuclear and internal Specialist in oncology, nuclear and internal medicinemedicine
Kotka May 2010Kotka May 2010
![Page 2: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/2.jpg)
OverviewOverview
Neuroendocrine tumours: clinic and treatmentNeuroendocrine tumours: clinic and treatment Indications for imagingIndications for imaging SomatostatinSomatostatin 111111In-DTPA-octreotide (OctreoScan®)In-DTPA-octreotide (OctreoScan®)
ImagingImaging Normal FindingsNormal Findings Uptake scaleUptake scale Typical and unusual findingsTypical and unusual findings
Some patients, that you have sent to us for treatment Some patients, that you have sent to us for treatment Thank youThank you
![Page 3: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/3.jpg)
Neuroendocrine tumoursNeuroendocrine tumours
A small tumour group, with lots to learn A small tumour group, with lots to learn from!from!
During the last decade, an evolving model for During the last decade, an evolving model for designing and studying tracers in nuclear designing and studying tracers in nuclear imaging and therapyimaging and therapy
![Page 4: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/4.jpg)
Neuroendocrine tumoursNeuroendocrine tumoursGastro-entero-pancreaticoduodenal tumours (GEP-NETs)Gastro-entero-pancreaticoduodenal tumours (GEP-NETs)
””Carcinoids”: derived from embryonal foregut, midgut Carcinoids”: derived from embryonal foregut, midgut and hindgutand hindgut Foregut och midgut carcinoids: Production of Foregut och midgut carcinoids: Production of
5-HIAA (classic carcinoid syndrom: flushing, 5-HIAA (classic carcinoid syndrom: flushing, palpitation, diarrhea)palpitation, diarrhea)
Endocrine pankreaticoduodenal tumours (EPTs): Endocrine pankreaticoduodenal tumours (EPTs): functioning or non-functioningfunctioning or non-functioning Different associated hormonal syndromsDifferent associated hormonal syndroms
Gastrin, insulin, glucagon, VIP, somatostatin, Gastrin, insulin, glucagon, VIP, somatostatin, ACTH….ACTH….
![Page 5: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/5.jpg)
Neuroendocrine tumoursNeuroendocrine tumours
Pheochromocytomas /paragangliomasPheochromocytomas /paragangliomas Medullary thyroid carcinomasMedullary thyroid carcinomas Neuroendocrine cancers/ neuroendocrine Neuroendocrine cancers/ neuroendocrine
tumours of unknown origintumours of unknown origin ……………………..many rare entities..many rare entities
![Page 6: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/6.jpg)
Treatment overviewTreatment overview
SurgerySurgery Local destruction of livermetastasesLocal destruction of livermetastases
LeverembolisationLeverembolisation Radiofrequency ablationRadiofrequency ablation
Biological treatment Biological treatment (alpha-Interferon, (alpha-Interferon, SomatostatinanalogsSomatostatinanalogs))
ChemotherapyChemotherapy RadiationRadiation
External BeamExternal Beam Brachytherapy of livermetastases (SIR-spheres®)Brachytherapy of livermetastases (SIR-spheres®) Peptide receptor radionuclide therapy (PRRT)Peptide receptor radionuclide therapy (PRRT)
![Page 7: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/7.jpg)
Indications for diagnostic imaging Indications for diagnostic imaging
Staging of recently diagnosed patientsStaging of recently diagnosed patients Finding small tumours: important in case of Finding small tumours: important in case of
significant hormone production (pancreas) , or to significant hormone production (pancreas) , or to rule out extrahepatic disease prior to rule out extrahepatic disease prior to livertransplantationlivertransplantation
Receptor status before chosing therapyReceptor status before chosing therapy Follow-up of therapyFollow-up of therapy
![Page 8: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/8.jpg)
If finding small tumours is If finding small tumours is important…..important…..
……Maybe PET/CT is your choiceMaybe PET/CT is your choice
![Page 9: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/9.jpg)
11C-5-HTP(HTP)
![Page 10: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/10.jpg)
11C
![Page 11: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/11.jpg)
![Page 12: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/12.jpg)
11C-5-hydroxytryptophan
![Page 13: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/13.jpg)
If the receptor status is important…..If the receptor status is important…..
Imaging with somatostatin Imaging with somatostatin analogs! analogs!
![Page 14: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/14.jpg)
SomatostatinSomatostatin
![Page 15: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/15.jpg)
SomatostatinSomatostatin
![Page 16: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/16.jpg)
SomatostatinSomatostatin
Regulatory hormone, thatRegulatory hormone, that Inhibits growth hormoneInhibits growth hormone Inhibits/suppresses release of a row of Inhibits/suppresses release of a row of
gastrointestinal hormones (VIP, glucagon, gastrointestinal hormones (VIP, glucagon, cholecystokinin, gastrin, motilin, secretin….)cholecystokinin, gastrin, motilin, secretin….)
Suppresses the exocrine function of the Suppresses the exocrine function of the pancreaspancreas
Inhibits TSHInhibits TSH
![Page 17: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/17.jpg)
Octreotide (Sandostatin®)Octreotide (Sandostatin®)
![Page 18: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/18.jpg)
Somatostatin receptorsSomatostatin receptors
5 subtypes (sstr1- sstr5)5 subtypes (sstr1- sstr5) Sstr2 predominant in neuroendocrine tumours, Sstr2 predominant in neuroendocrine tumours,
followed by sst5followed by sst5 Octreotide somatostatin analog predominantly Octreotide somatostatin analog predominantly
used in the clinic (Sandostatin®, Sandostatin used in the clinic (Sandostatin®, Sandostatin LAR®), predominant affinity for sstr2 and 5LAR®), predominant affinity for sstr2 and 5
Golden standard för sstr- diagnostic in nuclear Golden standard för sstr- diagnostic in nuclear medicine: OctreoScan® (medicine: OctreoScan® (111111In-DTPA-octreotide)In-DTPA-octreotide)
![Page 19: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/19.jpg)
Normal distributionNormal distribution
Anterior Posterior
Physiological uptake in:
PituitaryThyroidLiverSpleenKidneysAdrenalsGut
![Page 20: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/20.jpg)
OctreoScan® imagingOctreoScan® imaging
Whole body scan: Scanning time (at least 30min)Whole body scan: Scanning time (at least 30min) SPECT/CT: so much better informationSPECT/CT: so much better information Activity 200MBq for adults; one kit per patientActivity 200MBq for adults; one kit per patient Imaging after 24 hrs sufficient , SPECT/CT and patient Imaging after 24 hrs sufficient , SPECT/CT and patient
preparation importantpreparation important Laxation:Laxation: Toilax® (Bisacodyl) Toilax® (Bisacodyl)
2 tabl. à 5mg noon and evening on day of injection2 tabl. à 5mg noon and evening on day of injection
klysma Toilax® morning of examination dayklysma Toilax® morning of examination day Liquid food 12.00 noon inj. day until examination is Liquid food 12.00 noon inj. day until examination is
finishedfinished
![Page 21: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/21.jpg)
Intensity of uptakeIntensity of uptake
Arbitrary scale (according to Krenning): uptake in Arbitrary scale (according to Krenning): uptake in relation to liver uptakerelation to liver uptake
0: no uptake0: no uptake 1: weak uptake, less than liver1: weak uptake, less than liver 2: moderate uptake equivalent to liver2: moderate uptake equivalent to liver 3: intense uptake, higher than liver3: intense uptake, higher than liver 4:very intense uptake, much higher than liver, more 4:very intense uptake, much higher than liver, more
intense than spleen/kidneysintense than spleen/kidneys
![Page 22: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/22.jpg)
OctreoScan® 1996: both diagnostics and OctreoScan® 1996: both diagnostics and therapytherapy
![Page 23: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/23.jpg)
Normal uptakeNormal uptake
![Page 24: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/24.jpg)
Grade 1
Grade 3-4
Grade 3
![Page 25: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/25.jpg)
Grade 4: Patient with hindgut Grade 4: Patient with hindgut carcinoidcarcinoid
![Page 26: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/26.jpg)
Imaging: Midgut carcinoidImaging: Midgut carcinoid
ant post
Staticposterior
Staticanterior
?
![Page 27: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/27.jpg)
Tornado signTornado sign
![Page 28: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/28.jpg)
Massive mesenterial dissemination Massive mesenterial dissemination
![Page 29: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/29.jpg)
…………and one thoracic lymph nodeand one thoracic lymph node
![Page 30: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/30.jpg)
Midgut High proliferationMidgut High proliferation
Ant post ant post
![Page 31: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/31.jpg)
Cardiac metastasesCardiac metastases
![Page 32: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/32.jpg)
Right liver lobe previously treated Right liver lobe previously treated with embolizationwith embolization
![Page 33: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/33.jpg)
Left liver lobe: untreated metastasesLeft liver lobe: untreated metastases
![Page 34: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/34.jpg)
![Page 35: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/35.jpg)
Imaging: InsulinomaImaging: Insulinoma
Insulinomas: predominant pancreatic endocrine Insulinomas: predominant pancreatic endocrine tumour grouptumour group
Better prognosis than other GEP NETsBetter prognosis than other GEP NETs Excellent surgical curation rate, Excellent surgical curation rate, if localizedif localized express in only 50% sstr2express in only 50% sstr2 Malignant insulinomas may have higher expression Malignant insulinomas may have higher expression
of sstr2of sstr2
![Page 36: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/36.jpg)
73yr-old lady with hypoglycemic fits73yr-old lady with hypoglycemic fits
![Page 37: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/37.jpg)
Isolated insulinoma in ectopic Isolated insulinoma in ectopic pancreatic tissuepancreatic tissue
![Page 38: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/38.jpg)
Patient alive and well……..Patient alive and well……..
Symptom free now 7 years after surgerySymptom free now 7 years after surgery Celebrating her 80th birthday this yearCelebrating her 80th birthday this year
![Page 39: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/39.jpg)
Malignant InsulinomaMalignant Insulinoma
![Page 40: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/40.jpg)
Malignant InsulinomaMalignant Insulinoma
![Page 41: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/41.jpg)
Malignant InsulinomaMalignant Insulinoma
![Page 42: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/42.jpg)
Follow up of therapyFollow up of therapy
Somatostatin receptor densitySomatostatin receptor density may vary in different metastases in the same may vary in different metastases in the same
patientpatient May change over timeMay change over time Somatostatin receptor scintigraphy should Somatostatin receptor scintigraphy should
only be interpreted together with radiological only be interpreted together with radiological informationinformation
![Page 43: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/43.jpg)
56y-old lady, atypical bronchial 56y-old lady, atypical bronchial carcinoidcarcinoid
Previously pulmectomyPreviously pulmectomy 3 years later pain in the back3 years later pain in the back Treatment with temozolomide (Temodal®)Treatment with temozolomide (Temodal®)
![Page 44: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/44.jpg)
Follow-up with OctreoScan®: not a Follow-up with OctreoScan®: not a given indication….given indication….
Baseline after 3 6 9 courses
![Page 45: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/45.jpg)
……but it may help to interprete your but it may help to interprete your CT-findingsCT-findings
![Page 46: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/46.jpg)
Cave: Receptor up-regulationCave: Receptor up-regulation
Treatment can change receptor expressionTreatment can change receptor expression New uptake does not necessarily need to represent New uptake does not necessarily need to represent
new lesions.new lesions.
Example of a patient with malignant Example of a patient with malignant pheochromocytomapheochromocytoma
![Page 47: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/47.jpg)
OctreoScan®OctreoScan®
![Page 48: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/48.jpg)
OctreoScan®OctreoScan® 123123I MIBGI MIBG
![Page 49: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/49.jpg)
Malignant PheochromocytomaMalignant Pheochromocytoma
Diagnostic imaging Therapy123I-MIBG 111In-Oscan 131I-MIBG 177Lu-DOTA-tate October 08 October 08 April 09
![Page 50: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/50.jpg)
TreatmentTreatment
![Page 51: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/51.jpg)
Treatment with radiolabelled Treatment with radiolabelled somatostatin analogssomatostatin analogs
A renaissance for imaging with A renaissance for imaging with 111111In-DTPA-In-DTPA-octreotide?!!octreotide?!!
![Page 52: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/52.jpg)
OctreotideOctreotide
![Page 53: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/53.jpg)
LutetiumLutetium
![Page 54: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/54.jpg)
177177Lu-DOTA-TyrLu-DOTA-Tyr33-Octreotate-Octreotate
![Page 55: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/55.jpg)
![Page 56: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/56.jpg)
111111In-DTPA-octreotide In-DTPA-octreotide 177177Lu-DOTA-octreotate Lu-DOTA-octreotate 24h24h
ant post ant post antant post post
![Page 57: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/57.jpg)
Diagnostic images and therapy control: Diagnostic images and therapy control: tumour-to-backgroundtumour-to-background
Oscan 24h Lu 0h 24h 96h 168h
![Page 58: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/58.jpg)
Treatments with 177Lu-DOTA-octreotateTreatments with 177Lu-DOTA-octreotate
0
50
100
150
200
250
Antal behandlingar
2005 2006 2007 2008 2009
![Page 59: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/59.jpg)
![Page 60: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/60.jpg)
Hindgut carcinoid: therapy 1-4Hindgut carcinoid: therapy 1-4
![Page 61: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/61.jpg)
Effect of therapy over timeEffect of therapy over time
Feb 09 April 09 July 09 Aug 09 Jan 10
![Page 62: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/62.jpg)
![Page 63: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/63.jpg)
![Page 64: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/64.jpg)
Ther 1Ther 1 Ther 6Ther 6
![Page 65: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/65.jpg)
Glomerular filtration rate before therapyGlomerular filtration rate before therapy
Before ther1 ther2 ther3 ther4 ther5 ther6
![Page 66: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/66.jpg)
Therapy effects 2: Therapy effects 2: Patient with hindgut carcinoidPatient with hindgut carcinoid
ther 1 ther 2 ther 3 ther 4 ther 5 ther 6
Anterior view , 177Lu-DOTA-octreotate 24 h pi
![Page 67: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/67.jpg)
Therapy 1Therapy 1 Therapy 3Therapy 3
![Page 68: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/68.jpg)
CT-interpretation: take advantage of CT-interpretation: take advantage of your scintigraphy!your scintigraphy!
Therapy 1Therapy 1 Therapy 6Therapy 6
![Page 69: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/69.jpg)
Therapy 1Therapy 1 Therapy 6Therapy 6
![Page 70: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/70.jpg)
177Lu-DOTA-octreotate therapyResults from Rotterdam
Kwekkeboom et al, JCO, 2008
Result 3 months after completed therapy(n=310):Result 3 months after completed therapy(n=310):
CRCR 55 (2%)(2%)
PRPR 8686 (28%)(28%) 46%46%
MRMR 5151 (16%)(16%)
SDSD 107107 (35%)(35%)
PDPD 6161 (20%)(20%)
4% with SD or MR improved further after 6 months
5% with SD or MR improved further after 12 months
![Page 71: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/71.jpg)
Thank you toThank you to
Mattias Sandström and collegue hospital physicistsMattias Sandström and collegue hospital physicists Prof emeritus Hans Lundqvist (Radiophysics) Prof emeritus Hans Lundqvist (Radiophysics) Prof Barbro Eriksson och Prof Kjell Öberg, endocrine oncologyProf Barbro Eriksson och Prof Kjell Öberg, endocrine oncology Doc Dan GranbergDoc Dan Granberg Prof Anders SundinProf Anders Sundin Collegues an staff at the department of nuclear medicine, Collegues an staff at the department of nuclear medicine,
Uppsala Academical HospitalUppsala Academical Hospital Research collegues and friends at RudbecklaboratorietResearch collegues and friends at Rudbecklaboratoriet Med kand Daniel LindholmMed kand Daniel Lindholm Our patients, and……….Our patients, and……….
![Page 72: Diagnostic imaging with 111In-DTPA-octreotide: Clinical impact on the management of patients with neuroendocrine tumours Ulrike Garske MD Specialist in](https://reader030.vdocuments.site/reader030/viewer/2022033022/56649d8d5503460f94a74bef/html5/thumbnails/72.jpg)
… … Thank You for inviting me to Thank You for inviting me to beautiful Finland !beautiful Finland !